Accenture Up on Partnership with Anthropic; Novo Nordisk Falls on Turnaround | Stock Movers
Community Score: 50% | 134 views | 3w
0 community ratings: null thumbs up, null thumbs down
On this episode of Stock Movers: - Novo Nordisk (NVO) shares are lower as it disappointed investors hoping for concrete turnaround plans from Chief Executive Officer Mike Doustdar after losing its lead in the obesity market to Eli Lilly & Co. The company pledged to launch more than five blockbusters and deliver more than $23 billion in new sales in coming years, but investors are selling shares due to lack of concrete news. - Arhaus (ARHS) is moving after Jefferies upgraded the furniture company to buy from hold, writing that it has “newfound optimism on the retailer’s strategy to elevate brand awareness” and improve market share. - Accenture (ACN) is up on news Anthropic is partnering with Accenture to test the safety of its advanced artificial intelligence models by embedding evaluators from the consulting firm directly within its operations. -------- Watch Bloomberg Radio LIVE on YouTube Weekdays 7am-6pm ET Saturday & Sunday 7am-10am ET WATCH HERE: http://bit.ly/3vTiACF Follow u
Tags: Accenture PLC, Alexis Christoforous, Drugs, Economy, Investing, Markets, Novo Nordisk A/S, Ozempic, Paul Sweeney, Spending, Stock Movers, Weight loss, artificial intelligence, consumer, earnings, jess menton, medication, semiconductors, stocks, tech
More from Bloomberg Podcasts
- Follow the Money All the Way to Carney's Canada — Score: 50%
- Daybreak Weekend: US CPI, Europe Energy, RBA Decision | Bloomberg Daybreak: Europe Edition — Score: 50%
- Bloomberg Money: Credit Card Indicators and Golf's Changing Fanbase | Bloomberg Intelligence — Score: 50%
- We hear you! | Bloomberg Hot Pursuit! — Score: 50%
- Bloomberg Businessweek Weekend - August 7th, 2026 | Bloomberg Businessweek — Score: 50%
- Team Favorite: AI-Era Internet, Spaceport Investment, Bolivia’s Investability | Wall Street Week — Score: 50%